Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases. The company's leading product candidate has the potential to address the significant unmet medical needs of the large multiple sclerosis (MS) patient population.
Opexa Therapeutics, Inc. was established in 2004 through the merger of two independent companies PharmaFrontiers and Opexa Pharmaceuticals. PharmaFrontiers had licensed novel stem cell technology from the University of Chicago and Opexa Pharmaceuticals had licensed novel T-cell technology from Baylor College of Medicine. The bringing together of these two novel and independent platforms propelled Opexa Therapeutics, Inc. to the forefront of cell therapy where it remains a leading force today.
Opexa is located in The Woodlands, Texas north of Houston on two acres of forested land in the research park and houses both its cGMP facility, research laboratories and corporate offices.